V
Vaxeleron develops next-generation RNA therapeutics utilizing a proprietary trans-amplifying RNA replicon platform. This technology facilitates sustained protein expression from minimal RNA input, enabling potent vaccines and therapies at reduced doses. The company applies this platform to advance precision medicine, particularly in developing personalized RNA-based cancer treatments.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Vaxeleron develops next-generation RNA therapeutics utilizing a proprietary trans-amplifying RNA replicon platform. This technology facilitates sustained protein expression from minimal RNA input, enabling potent vaccines and therapies at reduced doses. The company applies this platform to advance precision medicine, particularly in developing personalized RNA-based cancer treatments.